Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma

Fig. 5

IQS019 impairs tumor growth and homing of B lymphoid cells to spleen in vivo. a SCID mice were inoculated with UPN-1 cells and began treatment at day 10 post-inoculation with 2 or 10 mg/kg IQS019-2MeSO3H or equal volume of vehicle. IQS019-2MeSO3H was administrated 5 days a week for 2 weeks. b Lower panel, intratumoral glucose uptake was evaluated in representative mice injected intravenously with an IR800-labeled 2-deoxy glucose probe 24 h prior sacrifice, and visualized with an Odyssey infra-red scanner (Li-Cor). Upper panel, relative fluorescence quantification by means of the Image Studio software shows markedly reduced glucose uptake in tumor masses from mice receiving IQS019-2MeSO3H, when compared to vehicle-treated animals. c Immunostaining of consecutive sections from representative UPN-1-derived tumors, showing the decrease of proliferation and the induction of apoptosis accompanying the downregulation of p-Syk, p-Lyn and p-Btk upon IQS019-2MeSO3H treatment (magnification 200X). d Mice were injected intravenously with DOHH-2 cells and, after one week, received a 2 mg/kg dose of IQS019-2MeSO3H or vehicle, daily, for up to 14 days. Mice were then sacrificed and human (CD45+) malignant B cells were recounted from spleen as described in methods section (statistical significance: * p < 0.05). e In each treatment group, CD45+/CD20+ human B cells isolated from n = 3 representative animals, were labeled with anti-p-Syk, anti-p-Lyn, or anti-p-Btk antibody, and fluorescence was recorded on a cytometer. Shown are the relative r values among control and vehicle group, calculated for each phospho-kinase

Back to article page